Mizuho lowered the firm’s price target on GoodRx (GDRX) to $4 from $5 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Challenging Outlook for GoodRx Holdings Amid Structural and Market Pressures
- Buy Rating for GoodRx Holdings: Strategic Initiatives and Growth Prospects Amid Challenges
- GoodRx Holdings Reports Stable Q3 2025 Performance
- GoodRx Earnings Call: Growth Amid Challenges
- GoodRx reports Q3 adjusted EPS 8c, consensus 9c